Page 1

Immix Biopharma Announces 89 % Complete Response Rate at Interim Update Across All NEXICART - 2 Patients , with MRD- Negativity Indicating Potential to Reach up to 98 % Complete Response Rate , Supporting Potential Best - in - Class Therapy for